CMIC : Notice of Revision of Full-Year Earnings Forecast

July 29, 2022

To the press and whom it may concern,

Company name: CMIC HOLDINGS Co., Ltd.

Representative: Kazuo Nakamura, Representative Director and CEO （TSE Prime Code No. 2309）

Inquiries: Wataru Mochizuki, Corporate Director and CFO （Phone: [phone]）

Notice of Revision of Full-Year Earnings Forecast

CMIC HOLDINGS Co., Ltd. (the "Company") hereby announces the following revisions to the forecasts of the full-year consolidated results announced on April 28, 2022 for the fiscal year ending September 2022.

Notes

1．Revision of FY2022 Full-year Forecast (October 1, 2021 to September 30, 2022)

	Sales		Operating		Ordinary		Profit	Earnings per
		income			attributable to	share
				income		owners of
							parent
	Millions of yen		Millions of yen		Millions of yen		Millions of yen	Yen
Previous forecast (A)	97,000	7,600	7,800	3,900	217.30
Current revised	106,000	8,600	9,200	4,500	254.49
forecast (B)
Increase (B-A)	9,000	1,000	1,400	600	-
Rate of change (%)	9.3	13.2	17.9	15.4	-
(Reference) Results for the	85,788	4,920	5,091	2,023	111.85
previous fiscal year (FY2021)

(Reasons for amendment)

The outlook for the fiscal year ending September 30, 2022, incorporates the outlook for future work related to COVID-19 and the impact of the situation in Ukraine on our business, based on information available at this time.

For COVID-related operations, we expect therapeutic drug and vaccine development projects will continue, and the number of inquiries from local governments are expected to increase due to another wave of COVID.

The situation in Russia and Ukraine has no direct impact on our business, as we do not operate any business bases in either country. The impact of the situation on our business is expected to be limited, although there will be price increases in energy, raw materials,

packaging materials, and other items.

Based on the above, we have revised upward our full-year forecasts for the fiscal year ending September 30, 2022, to net sales of 106,000 million yen, operating income of 8,600 million yen, ordinary income of 9,200 million yen, and net income attributable to owners of the parent of the company of 4,500 million yen, respectively, in light of continued strong performance in vaccine development and vaccination support services for new coronavirus infection during the first half of the current fiscal year.